The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia
Status:
Recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm study to evaluate the safety and efficacy of Ibrutinib in
subjects with refractory/relapsed autoimmune hemolytic anemia.